Clinical Course, Immunogenicity, and Efficacy of BNT162b2 mRNA Vaccination Against SARS-CoV-2 Infection in Liver Transplant Recipients

Clinical Course, Immunogenicity, and Efficacy of BNT162b2 mRNA Vaccination Against SARS-CoV-2 Infection in Liver Transplant Recipients

10.1097/TXD.0000000000001537

Saved in:

Bibliographic Details
Main Authors:	Tan, Eunice X, Lim, Wen Hui, Thong, Elizabeth, Chavatte, Jean-Marc, Zhang, Jinyan, Lim, Jonathan, Jin, Jocelyn Y, Lim, Daniel RX, Kang, Jaclyn YT, Tang, Ansel Shao Pin, Chan, Kai En, Tan, Caitlyn, Tan, Shi Ni, Nah, Benjamin, Huang, Daniel Q, Wang, Lin-Fa, Tambyah, Paul A, Somani, Jyoti, Young, Barnaby, Muthiah, Mark D
Other Authors:	MEDICINE
Format:	Article
Language:	English
Published:	LIPPINCOTT WILLIAMS & WILKINS 2023
Subjects:	Science & Technology Life Sciences & Biomedicine Transplantation COVID-19
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/245630
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Similar Items

Clinical course, immunogenicity, and efficacy of BNT162b2 mRNA vaccination against SARS-CoV-2 infection in liver transplant recipients
by: Tan, Eunice X., et al.
Published: (2024)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
by: Rebecca P. Payne, et al.
Published: (2022)

Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases
by: Napaporn Chantasrisawad, et al.
Published: (2022)

Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases
by: Chantasrisawad N.
Published: (2023)

Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB
by: Chang, Zi Wei, et al.
Published: (2023)

Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents
by: Mansanguan S.
Published: (2023)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
by: Lim, Xin Rong, et al.
Published: (2021)

Polyneuritis Cranialis Associated with BNT162b2 mRNA COVID-19 Vaccine in a Healthy Adolescent
by: Pimchanok Kulsirichawaroj, et al.
Published: (2022)

Polyneuritis Cranialis Associated with BNT162b2 mRNA COVID-19 Vaccine in a Healthy Adolescent
by: Kulsirichawaroj P.
Published: (2023)

Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
by: Low, Jia Ming, et al.
Published: (2021)

Effectiveness of BNT162b2 vaccine against omicron in children 5 to 11 years of age
by: Tan, Sharon H. X., et al.
Published: (2023)

BNT162b2 vaccination induces SARS-CoV-2 specific antibody secretion into human milk with minimal transfer of vaccine mRNA
by: Low, Jia Ming, et al.
Published: (2023)

BNT162b2 mRNA SARS-CoV-2 vaccination does not cause upregulation of endothelial activation markers or hypercoagulability: A prospective, single-arm, longitudinal study
by: Lim, Xin Rong, et al.
Published: (2023)

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
by: Renia, Laurent, et al.
Published: (2022)

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
by: Suvimol Niyomnaitham, et al.
Published: (2022)

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
by: Niyomnaitham S.
Published: (2023)

Anaphylatoxin Complement 5a in Pfizer BNT162b2-Induced Immediate-Type Vaccine Hypersensitivity Reactions
by: Lim, Xin Rong, et al.
Published: (2023)

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
by: Wang, Bei, et al.
Published: (2022)

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
by: Renia, Laurent, et al.
Published: (2023)

Ventricular tachycardia from myocarditis following COVID-19 vaccination with tozinameran (BNT162b2, Pfizer-BioNTech)
by: Lin, Weiqin, et al.
Published: (2022)

Potent pan huACE2-dependent sarbecovirus neutralizing monoclonal antibodies isolated from a BNT162b2-vaccinated SARS survivor
by: Chia, Wan Ni, et al.
Published: (2023)

Robust sars?cov?2 antibody responses in asian covid?naïve subjects 180 days after two doses of bnt162b2 mrna covid?19 vaccine
by: Lau, Chin-Shern, et al.
Published: (2022)

The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial
by: Chantasrisawad N.
Published: (2023)

Safety and immunogenicity of intradermal administration of fractional dose CoronaVac<sup>®</sup>, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination
by: Chatsiricharoenkul S.
Published: (2023)

Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants
by: Niyomnaitham S.
Published: (2023)

Toxic epidermal necrolysis after first dose of Pfizer-BioNTech (BNT162b2) vaccination with pharmacogenomic testing
by: Siripipattanamongkol N.
Published: (2023)

BNT162b2 vaccine induced variant-specific immunity, safety and risk of Omicron breakthrough infection in children aged 5 to 11 years: a cohort study
by: Yung, Chee Fu, et al.
Published: (2024)

Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5–11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial
by: Wittawatmongkol O.
Published: (2023)

Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals
by: Goh, Yun Shan, et al.
Published: (2023)

Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals
by: Goh, Yun Shan, et al.
Published: (2023)

Human Milk Antibodies after BNT162b2 Vaccination Exhibit Reduced Binding against SARS-CoV-2 Variants of Concern
by: Low, Jia Ming, et al.
Published: (2023)

Human Milk Antibodies Elicited by BNT162b2 Vaccination have reduced activity against SARS-CoV-2 Variants of Concern
by: Low, Jia Ming, et al.
Published: (2023)

BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
by: Yung, Chee Fu, et al.
Published: (2023)

Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial
by: Niyomnaitham S.
Published: (2023)

Recipient of the Student Leadership Award
by: Macatangay, Abraham Daniel
Published: (1999)

Immunogenicity of Vero Cell Culture-derived Japanese Encephalitis Vaccine in Pediatric and Young Hematopoietic Stem Cell Transplantation Recipients
by: Surapat Assawawiroonhakarn, et al.
Published: (2022)

Predictors of Non-adherence to Immunosuppressive Therapy in Asian Liver Transplant Recipients
by: Hartono J.L., et al.
Published: (2018)

Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis
by: Meejun T.
Published: (2023)

We Forum, vol xiii No. 162 - Feb. 8, 1990
by: Burgos, Jr., Jose
Published: (1990)

Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years
by: Wanlapakorn N.
Published: (2023)